nach oben

BioDrugs

Erschienen in:

01.01.2008 | Novel Therapeutic Strategies

Ribonucleases as Novel Chemotherapeutics

The Ranpirnase Example

verfasst von: J. Eugene Lee, Professor Ronald T. Raines

Erschienen in: BioDrugs | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Ranpirnase, a cytotoxic ribonuclease from the frog Rana pipiens, is the archetype of a novel class of cancer chemotherapeutic agents based on homologs and variants of bovine pancreatic ribonuclease (RNase A). Ranpirnase in combination with doxorubicin is in clinical trials for the treatment of unresectable malignant mesothelioma and other cancers. The putative mechanism for ranpirnase-mediated cytotoxicity involves binding to anionic components of the extracellular membrane, cytosolic internalization, and degradation of transfer RNA leading to apoptosis. The maintenance of ribonucleolytic activity in the presence of the cytosolic ribonuclease inhibitor protein is a key aspect of the cytotoxic activity of ranpirnase. The basis for its specific toxicity for cancer cells is not known. This review describes the development of ranpirnase as a cancer chemotherapeutic agent.

Tafech A, Bassett T, Sparanese D, et al. Destroying RNA as a therapeutic approach. Curr Med Chem 2006; 13: 863–81PubMedCrossRef

Sloud M. Ribozymes and siRNAs: from structure to preclinical applications. Handb Exp Pharmacol 2006; 173: 223–42CrossRef

Schubert S, Kurreck J. Oligonucleotide-based antiviral strategies. Handb Exp Pharmacol 2006; 173: 261–87PubMedCrossRef

Rayburn ER, Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 2006; 11: 337–52PubMedCrossRef

Roehr B. Forivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998; 4: 14–6PubMed

Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711–9PubMedCrossRef

Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75–86PubMedCrossRef

Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173–84PubMedCrossRef

Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537–41PubMedCrossRef

10.

Marsden PA. RNA interference as potential therapy: not so fast. New Engl J Med 2006; 355: 953–4PubMedCrossRef

11.

Matoušek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol 2001; 129C: 175–91

12.

Leland PA, Raines RT. Cancer chemotherapy: ribonucleases to the rescue. Chem Biol 2001; 8: 405–13PubMedCrossRef

13.

Makarov AA, Ilinskaya ON. Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 2003; 540: 15–20PubMedCrossRef

14.

Benito A, Ribó M, Vilanova M. On the track of antitumor ribonucleases. Mol Biosyst 2005; 1: 294–302PubMedCrossRef

15.

Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006; 28: 1615–22PubMedCrossRef

16.

D’Alessio G, Riordan JF, editors. Ribonucleases: structures and functions. New York: cademic Press 1997

17.

Raines RT. Ribonuclease A. Chem Rev 1998; 98: 1045–65PubMedCrossRef

18.

D’Alessio G, Di Donate A, Mazzarella L, et al. Seminal ribonuclease: the importance of diversity. In: D’Alessio G, Riordan JF, editors. Ribonucleases: structures and functions. New York: Academic Press, 1997: 383–423

19.

Matoušek J, Souček J, Slavik T, et al. Comprehensive comparison of the cytotoxic activities of Onconase and bovine seminal ribonuclease. Comp Biochem Physiol 2003; 136C: 343–56

20.

Costanzi J, Sidransky D, Navon A, et al. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005; 23: 643–50PubMedCrossRef

21.

Pavlakis N, Vogelzang NJ. Ranpirnase, an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 2006; 6: 391–9PubMedCrossRef

22.

Saxena SK, Shogen K, Ardelt W. Onconase® and its therapeutic potential. Lab Med 2003; 34: 380–7CrossRef

23.

Shogen K, Yoan WK. Antitumor activity in extracts of Leopard frog (Rana pipiens) embryos. 27th Annual Eastern Colleges Science Conference; 197 Apr 28; State College (PA).

24.

Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem 1991; 266: 245–51PubMed

25.

Dyer KD, Rosenberg HF. The RNase A superfamily: generation of diversity and innate host defense. Mol Divers 2006; 10: 585–97PubMedCrossRef

26.

Liao YD, Wang JJ. Yolk granules are the major compartment for bullfrog (Rana catesbeiana) oocyte-specific ribonuclease. Eur J Biochem 1994; 222: 215–20PubMedCrossRef

27.

Chen S, Le SY, Newton DL, et al. A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3′ UTR of unusual length and structure. Nucleic Acids Res 2000; 28: 2375–82PubMedCrossRef

28.

Darzynkiewicz Z, Carter SP, Mikulski SM, et al. Cytostatic and cytotoxic effect of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinet 1988; 21: 169–82PubMed

29.

Lee I, Kalota A, Gewirtz AM, et al. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 2007; 27: 299–307PubMed

30.

Mosimann SC, Ardelt W, James MNG. Refined 1.7 Å x-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol 1994; 236: 1141–53PubMedCrossRef

31.

Raines RT. Active site of ribonuclease A. In: Zenkova MA, editor. Artificial nucleases. Heidelberg: Springer, 2004: 19–32CrossRef

32.

Welker E, Hathaway L, Xu G, et al. Oxidative folding and N-terminal cyclization of Onconase. Biochemistry 2007; 46: 5485–93PubMedCrossRef

33.

Merritt EA, Murphy MEP. Raster3D Version 2.0, a program for photorealistic molecular graphics. Acta Crystallogr D Biol Crystallogr 1994; 50: 869–73PubMedCrossRef

34.

Lee JE, Raines RT. Contribution of active-site residues to the function of Onconase, a ribonuclease with antitumoral activity. Biochemistry 2003; 42: 11443–50PubMedCrossRef

35.

Gorbatyuk VY, Tsai CK, Chang CF, et al. Effect of N-terminal and Met23 mutations on the structure and dynamics of Onconase. J Biol Chem 2004; 279: 5772–80PubMedCrossRef

36.

Merlino A, Mazzarella L, Carannante A, et al. The importance of dynamic effects on the enzyme activity: x-ray structure and molecular dynamics of Onconase mutants. J Biol Chem 2005; 280: 17953–60PubMedCrossRef

37.

Koshland DE. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci USA 1958; 44: 98–104PubMedCrossRef

38.

Lee JE, Bae E, Bingman CA, et al. Structural basis for catalysis by Onconase. J Mol Biol 2008; 375: 165–77PubMedCrossRef

39.

Saxena SK, Sirdeshmukh R, Ardelt W, et al. Entry into cells and selective degradation of fRNAs by a cytotoxic member of the RNase A family. J Biol Chem 2002; 277: 15142–6PubMedCrossRef

40.

Suhasini AN, Sirdeshmukh R. Transfer RNA cleavages by Onconase reveal unusual cleavage sites. J Biol Chem 2006; 281: 12201–9PubMedCrossRef

41.

Notomista E, Catanzano F, Graziano G, et al. Onconase: an unusually stable protein. Biochemistry 2000; 39: 8711–8PubMedCrossRef

42.

Leland PA, Staniszewski KE, Kim B-M, et al. A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 2000; 477: 203–7PubMedCrossRef

43.

Arnold U, Schulenburg C, Schmidt D, et al. Contribution of structural peculiarities of Onconase to its high stability and folding kinetics. Biochemistry 2006; 45: 3580–7PubMedCrossRef

44.

Kim B-M, Kim H, Raines RT, et al. Glycosylation of Onconase increases it conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 2004; 315: 976–83PubMedCrossRef

45.

Johnson RJ, Chao T-Y, Lavis LD, et al. Cytotoxic ribonucleases: the dichotomy of Coulombic forces. Biochemistry 2007 Sep 11; 46(36): 10308–16PubMedCrossRef

46.

Wu Y, Mikulski SM, Ardelt W, et al. A cytotoxic ribonuclease: study of the mechanism of Onconase cytotoxicity. J Biol Chem 1993; 268: 10686–93PubMed

47.

Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003; 116: 313–24PubMedCrossRef

48.

Rodriguez M, Torrent G, Bosch M, et al. Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 2007; 120: 1405–11PubMedCrossRef

49.

Wu Y, Saxena SK, Ardelt W, et al. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem 1995; 270: 17476–81PubMedCrossRef

50.

Fuchs SM, Raines RT. Internalization of cationic peptides: the road less (or more?) traveled. Cell Mol Life Sci 2006; 63: 1819–22PubMedCrossRef

51.

Haigis MC, Kurten EL, Raines RT. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 2003; 31: 1024–32PubMedCrossRef

52.

Dickson KA, Haigis MC, Raines RT. Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 2005; 80: 349–74PubMedCrossRef

53.

Kajava AV. Structural diversity of leucine-rich repeat proteins. J Mol Biol 1998; 277: 519–27PubMedCrossRef

54.

Johnson RJ, McCoy JG, Bingman CA, et al. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 2007; 367: 434–49CrossRef

55.

Leland PA, Staniszewski KE, Kim B-M, et al. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 2001; 276: 43095–102PubMedCrossRef

56.

Rutkoski TJ, Kurten EL, Mitchell JC, et al. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol 2005; 354: 41–54PubMedCrossRef

57.

Deptala A, Halicka HD, Ardelt B, et al. Potentiation of tumor necrosis factor induced apoptosis by Onconase. Int J Oncol 1998; 13: 11–6PubMed

58.

Iordanov MS, Ryabinina OP, Wong J, et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease Onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000; 60: 1983–94PubMed

59.

Ardelt B, Ardelt W, Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2003; 2: 22–4PubMedCrossRef

60.

Iordanov MS, Wong J, Newton DL, et al. Differential requirement for the stress-activated protein kinase/c-Jun NH₂-terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun 2000; 4: 122–8PubMedCrossRef

61.

Grabarek J, Ardelt B, Du L, et al. Activation of caspases and serine proteases during apoptosis induced by Onconase (ranpirnase). Exp Cell Res 2002; 278: 61–71PubMedCrossRef

62.

Halicka HD, Ardelt B, Shogen K, et al. Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with Onconase. Int J Oncol 2007; 30: 841–7PubMed

63.

James AM, Ambrose EJ, Lowick JH. Differences between the electrical charge carried by normal and homologous tumour cells. Nature 1956; 177: 576–7PubMedCrossRef

64.

Slivinsky GG, Hymer WC, Bauer J, et al. Cellular electrophoretic mobility data: a first approach to a database. Electrophoresis 1997; 18: 1109–19PubMedCrossRef

65.

Kojima K. Molecular aspects of the plasma membrane in tumor cells. Nagoya J Med Sci 1993; 56: 1–18PubMed

66.

Fredman P. Glycosphingolipid tumor antigens. Adv Lipid Res 1993; 25: 213–34PubMed

67.

Halicka HD, Murakami T, Papageorgio CN, et al. Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by Onconase. Cell Prolif 2000; 33: 407–17PubMedCrossRef

68.

Rybak SM, Pearson JW, Fogler WE, et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with Onconase, an antitumor ribonuclease. J Natl Cancer Inst 1996; 88: 747–53PubMedCrossRef

69.

Juan G, Ardelt B, Li X, et al. Gl arrest of U937 cells by Onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/ CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia 1998; 12: 1241–8PubMedCrossRef

70.

Mikulski SM, Viera A, Ardelt W, et al. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 1990; 23: 237–46PubMed

71.

Mikulski SM, Viera A, Darzynkiewicz Z, et al. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66: 304–10PubMedCrossRef

72.

Lee I, Lee YH, Mikulski SM, et al. Effect of Onconase +/−tamoxifen on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol 2003; 530: 187–96PubMedCrossRef

73.

Mikulski SM, Ardelt W, Shogen K, et al. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990; 82: 151–3PubMedCrossRef

74.

Lee I, Lee YH, Mikulski SM, et al. Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by Onconase. Anticancer Res 2000; 20: 1037–40PubMed

75.

Mikulski SM, Grossman A, Carter P, et al. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol 1993; 3: 57–64PubMed

76.

Mikulski SM, Chun H, Mittelman A, et al. Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: comparison of Onconase with other cancer agents. Int J Oncol 1995; 6: 889–97PubMed

77.

Puccio C, Mittelman A, Chun H, et al. A new anticancer Rnase (Onconase): clinical trial in patients (pts) with breast cancer (BC) [abstract no. 242]. American Society of Clinical Oncology Annual Meeting; 1996 May 18–21; Philadelphia (PA)

78.

Vogelzang NJ, Aklilu M, Stadler WM, et al. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs 2001; 19: 255–60PubMedCrossRef

79.

Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20: 274–81PubMedCrossRef

80.

Newton DL, Hansen HJ, Mikulski SM, et al. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 2001; 97: 528–35PubMedCrossRef

Titel: Ribonucleases as Novel Chemotherapeutics
The Ranpirnase Example
verfasst von: J. Eugene Lee
Professor Ronald T. Raines
Publikationsdatum: 01.01.2008
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 1/2008
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200822010-00006

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Ribonucleases as Novel Chemotherapeutics

The Ranpirnase Example

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Vaccine Approaches to Prevent and Treat Prion Infection

Targeted Immunotherapy for Staphylococcal Infections

Fc-Based Cytokines

Dasatinib

Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

Convergence of Nanotechnology and Cardiovascular Medicine